Tryptamine Therapeutics
ENPSydney, Australia· Est.
Australian‑based biotech delivering IV psilocin therapies for neuropsychiatric disorders.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian‑based biotech delivering IV psilocin therapies for neuropsychiatric disorders.
NeuropsychiatryPainGastroenterologyEating Disorders
Technology Platform
Proprietary IV infusion of synthetic psilocin with precision dosing, formulation, and biomarker‑guided control to modulate 5‑HT2A receptors.
Opportunities
IV psilocin offers faster, controllable psychedelic therapy, opening pathways to hospital‑based treatments and partnerships with pharma seeking precision neuropsychiatric solutions.
Risk Factors
Regulatory uncertainty for intravenous psychedelics, safety profile validation, and competition from oral psychedelic programs could hinder commercialization.
Competitive Landscape
Differentiates from oral psychedelic competitors (e.g., COMPASS Pathways, Mind Medicine) through IV delivery, rapid onset/termination, and clinician‑controlled dosing, but must prove superior efficacy and safety.